Effect of Blue Light Blocking on Reducing Manic Symptoms in Bipolar Disorder
Launched by RAYAN NASSERDINE · Dec 18, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at whether wearing special orange glasses that block blue light can help reduce manic symptoms in people with Bipolar Disorder (BD). Participants in the study will be adults aged 18 to 70 who are currently hospitalized due to manic episodes. They will be randomly assigned to either wear the blue-light blocking glasses or regular clear glasses (which won’t provide any special treatment) for 10 days, along with their usual medication. The researchers want to see if the orange glasses can lead to a greater improvement in mood and behavior, as measured by a specific rating scale.
If you or a loved one is considering participation, it’s important to know that this study is focused on individuals who are currently experiencing manic symptoms and meet certain criteria. Those who have severe eye problems, are going through withdrawal from drugs or alcohol, or have previously used blue-light blocking glasses will not be eligible. The study is designed to gather important information while ensuring that participants' rights and privacy are respected.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients hospitalized with manic symptoms in HUG
- • Diagnostic of Bipolar Disorder according to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) criteria
- • aged 18-70 years
- Exclusion Criteria:
- • previous knowledge of blue-blocking glasses
- • not consenting to participate
- • severe eye disease or traumatic injury affecting both eyes.
- • withdrawal symptoms from any drug or alcohol at the time of admission (the start of the intervention will be delayed until withdrawal symptoms have ceased)
About Rayan Nasserdine
Rayan Nasserdine is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through rigorous clinical studies. With a focus on innovative therapies and a patient-centered approach, Rayan Nasserdine collaborates with leading healthcare professionals and research institutions to ensure the highest standards of scientific integrity and ethical conduct. By fostering a culture of collaboration and transparency, the organization aims to accelerate the development of groundbreaking treatments across various therapeutic areas, ultimately enhancing the quality of care for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Genève, Suisse, Switzerland
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported